Pharmaceutical

UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer

The UK NICE has declined to recommend Daiichi Sankyo's Enhertu for the treatment of advanced HER2-low breast cancer in adults.

Mar 7, 2024 - 18:00
UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer
The UK NICE has declined to recommend Daiichi Sankyo's Enhertu for the treatment of advanced HER2-low breast cancer in adults.
Read the original article

Tags:

Previous Article

Clinical trials in Africa: Where there is a challenge, there is an opportunity

Next Article

Alumis secures $259m to develop therapies for immune dysfunction

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Teladoc stock slides despite business growth, Medtronic CEO talks innovation

STAT+: Teladoc stock slides despite business growth, Me...

Oct 26, 2023

STAT+: FDA oncology head wants advisory panels to keep voting on new drugs

STAT+: FDA oncology head wants advisory panels to keep ...

Jun 6, 2023

NT-175 by Neogene Therapeutics for Head And Neck Squamo...

Dec 26, 2023